Brief: Decibel Therapeutics Receives FDA Clearance Of Ind Application For Db-Oto, A Gene Therapy Product Candidate Designed To Provide Hearing To Individuals With Otoferlin-Related Hearing Loss
17/10/2022 12:17
Oct 17 (Reuters) - Decibel Therapeutics Inc DBTX.O :
* DECIBEL THERAPEUTICS RECEIVES FDA CLEARANCE OF IND
APPLICATION
FOR DB-OTO, A GENE THERAPY PRODUCT CANDIDATE DESIGNED TO PROVIDE
HEARING TO INDIVIDUALS WITH OTOFERLIN-RELATED HEARING LOSS
Source text for Eikon: ID:nGNX54kkxX
Further company coverage: DBTX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Decibel Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Domo, BlackBerry, Rite Aid
U.S. STOCKS ON THE MOVE-Decibel Therapeutics, Affirm Holdings, Medtronic
Decibel rises on FDA's 'fast-track' tag for hearing-loss therapy
Brief: Decibel Therapeutics Says US Food And Drug Administration Had Granted Fast Track Designation For DB-OTO
Decibel Therapeutics Inc reports results for the quarter ended in June - Earnings Summary